You are here

Articles

Cancer Drugs Fund: CML Support is a signatory to a letter to The Times on November 4th, the day bosutinib is delisted

published: 21 September 2015

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

published: 16 September 2015

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

published: 4 August 2015

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for CML in chronic phase

published: 29 July 2015

Dasatinib, Imatinib, Associated With Differing Mutation Patterns in CML

published: 27 July 2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

published: 27 July 2015

Treatment-Free Remission by Tyrosine Kinase Inhibitor for Patients with Chronic Myeloid Leukemia

published: 20 July 2015

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

published: 17 July 2015

Tyrosine Kinase Inhibitors and Pregnancy

published: 7 July 2015

Network Meta-Analysis Shows a Significant Advantage of Nilotinib Over Imatinib in Chronic Myeloid Leukemia

published: 29 June 2015

Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment

published: 26 May 2015

RCC Drug Axitinib Could Treat TKI-Resistant CML

published: 26 May 2015

Interferon Could Help CML Patients Stop TKI Therapy

published: 26 May 2015

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

published: 9 May 2015

Laboratory recommendations for scoring deep molecular responses following treatment for CML

published: 9 May 2015

Bosutinib a Good Fourth-Line Option in CML

published: 6 May 2015

Bosutinib a Good Fourth-Line Option in CML

published: 11 April 2015

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in CML

published: 11 April 2015

2nd Generation TKIs prevent disease progression in high-risk (high CIP2A)CML patients

published: 25 March 2015

Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment

published: 25 March 2015